SCHEMBL20135375

SCHEMBL20135375

CCOC(=O)c1ccc(C(C)(C)C(=O)OCC#N)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
KMT2A Q03164 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.41
MAPK1 P28482 1/20 0.41
GAA P10253 3/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA7 P43166 2/20 0.40
CA9 Q16790 2/20 0.40
CA14 Q9ULX7 2/20 0.40
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12868073 0.80 KMT2A (0.54) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL20135688 0.76 MAPT (0.38) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL838555 0.76 CA12 (0.49) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL20134843 0.75 MAPT (0.40) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL20135150 0.74 MAPT (0.36) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL3376117 0.73 CA12 (0.49) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL28859561 0.72 CA12 (0.40) MAPTNPC1RAB9ASMN1; SMN2GAA
SCHEMBL15118626 0.72 LMNA (0.41) MAPTNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL20134922 0.71 CA12 (0.44) MAPTNPC1RAB9ASMN1; SMN2GAA
SCHEMBL14157046 0.71 CA12 (0.54) MAPTKMT2AMEN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 MAPT 4505/4885NPC1 4881/4885RAB9A 270/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 MAPT 4265/4885NPC1 4882/4885RAB9A 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.